Publication of phase III FRESCO-2 results evaluating fruquintinib in patients with previously treated colorectal cancer in The Lancet – Takeda and HutchMed

Takeda and HUTCHMED (China) Limited announced that results of the Phase III FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) were published in The Lancet.The publication provides details of the FRESCO-2 study results as of June 24, 2022. Summary results from this cut-off date were presented on September 12, 2022, at the European Society for […]